Mycophenolate mofetil therapy for children with frequently relapsing nephrotic syndrome

Mycophenolate mofetil therapy for children with frequently relapsing nephrotic syndrome - Mycophenolate mofetil therapy for children with frequently relapsing nephrotic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015052

Enrollment

Registered

2014-09-04

Start date

2012-08-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frequently relapsing nephrotic syndrome

Interventions

Oral mycophenolate mofetil 20-30 mg/kg divided into two times a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) children with frequently relapsing nephrotic syndrome 2) not to be able to maintain remission as tapering or stopping immunosuppresive drugs (steroids, ciclosporin, mizoribine etc.) 3) side effect of steroids or immunosuppresive drugs above are present or possible 4) to obtain informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
the rate of remission	—

Secondary

Measure	Time frame
non-relapse term	—

Countries

Japan

Contacts

Public ContactHitoshi Nakazato

Faculty of Education, Kumamoto University Department of School Health

hnakazat@kuh.kumamoto-u.ac.jp096-373-5191

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026